To the Editor: Catatonia is a syndrome associated with psychiatric or general medical conditions. 1 An autoactivation deficit is a syndrome related to lesions of the basal ganglia.
hours, in particular the motor disorders, the behavioral disinhibition, and the gegenhalten.
Nevertheless, residual clinical signs not typical of catatonia persisted. These included a persistence of stereotypical postures, the absence of motor initiation, a total absence of affective expression, and mental emptiness. It was possible to stimulate him, but he made no attempt to initiate conversation. Only by external stimulation was it possible to get any response from him. Although he had lost all initiative, we noted that he responded appropriately to reality and had normal orientation in time and space. With this clinical picture (stereotypic activities, inertia, the positive effect of external stimulation, mental emptiness, and blunted affect), together with the cerebral lesions observed on neurologic imaging (frontal and bipallidal lesions), we put forward the diagnosis of an auto-activation deficit. 2 In view of the dopaminergic agonist action of low-dose amisulpride, 6 we decided to offer the patient treatment with amisulpride (50 mg/day for 3 days, then 100 mg/day). After 7 days, we observed a significant improvement in his behavior, with fluent spontaneous speech and good emotional expression, but persistence of the frontal syndrome signs (disinhibition and perseveration). After a month of treatment, we did not observe any psychobehavioral disorders, and the renal function had returned to normal. He was transferred to the functional rehabilitation department because of residual external popliteal sciatic nerve paralysis from the compartment syndrome. Executive function tests performed after 2 months of treatment showed a residual prefrontal lesion with an attention disorder (selective and divided attention) and executive function disorders (changes in cognitive flexibility, rule discovery, and maintaining or changing rules). This prefrontal lesion later improved without any changes to the treatment.
We note that when amisulpride was prematurely stopped for a few days, the patient once again presented with symptoms of an auto-activation deficit, which disappeared again in a few days after reintroducing amisulpride (100 mg/day). He continues to be followed up in the addictology outpatients department, and no longer shows any signs of executive dysfunction. His treatment remains unchanged.
Bipallidal cerebral lesions have for a long time been linked to carbon monoxide poisoning, a symptom-free initial period, and characteristic radiologic signs being considered as a pathognomonic. Studies have shown heroin consumption to have been responsible for a reduction in neuronal density in the globus pallidus. 7 It can also cause bilateral symmetrical necrosis of the globus pallidus in 5% to 10% of cases. 8 In our case, the most likely physiopathologic hypothesis seems to be an ischemic origin, although direct neurotoxicity cannot be completely ruled out. 9 In the most severe cases, these lesions may cause an auto-activation deficit, 2 characterized by cognitivebehavioral inertia (disappearing after hetero-stimulation), mental emptiness, stereotypic activities, and a blunted affect, suggesting that the cortico-subcortical pathways have been damaged as a result of damage to the prefrontal cortex and/or the basal ganglia. 10 The sensorimotor, emotional, and motivational symptomatology are suggestive of disruption of the motor, limbic, and associative loops, where they converge in the globus pallidus. 11 We found no associated catatonic symptomatology with auto-activation deficit in the literature. Catatonia seems to be due to damage to the GABAergic transmission pathways, as shown by a rapid complete response to lorazepam, 1, 3 and to psychological and organic stress (sepsis). 12 We decided to treat the auto-activation deficit with low-dose amisulpride, in view of its clinical and cerebral blood flow similarities with deficit forms of schizophrenia. 5 At a dose of 100 mg/day, amisulpride preferentially blocks the high-affinity presynaptic dopaminergic receptors. The pharmacologic effect is probably due to an increase in dopaminergic transmission. 5 The clinical efficacy of low-dose amisulpride (a dopamine agonist) seems to indicate changes in the dopaminergic pathways in an auto-activation deficit, and also of the existence of a functional loop, in the case of a partial lesion. 13 
